Bisindolylmaleimides, a series of derivatives of a PKC inhibitor staurosporine, exhibit potential as anti-cancer drugs and have received considerable attention in clinical trials. This study aims to investigate the effects of a bisindolylmaleimide alkaloid 155Cl (BMA-155Cl) with a novel structure on autophagy and apoptosis in human hepatocarcinoma HepG-2 cells in vitro and in vivo. The cell poliferation was assessed with a MTT assay. Autophagy was evaluated by MDC staining and TEM analysis. Apoptosis was investigated using Annexin V-FITC/PI and DAPI staining. The antitumor effects were further evaluated in nude mice bearing HepG-2 xenografts, which received BMA-155Cl (10, 20 mg/kg, ip) for 18 days. Autophagy-and apoptosis-associated proteins and their mRNA levels were examined with Western blotting, immunohistochemistry, and RT-PCR. BMA-155Cl (2.5-20 μmol/L) inhibited the growth of HepG-2 cells with IC 50 values of 16.62±1.34, 12.21±0.83, and 8.44±1.82 μmol/L at 24, 48, and 72 h, respectively. Furthermore, BMA155Cl (5-20 μmol/L) dose-dependently induced autophagy and apoptosis in HepG-2 cells. The formation of autophagic vacuoles was induced by BMA-155Cl (10 μmol/L) at approximately 6 h and peaked at approximately 15 h. Pretreatment with 3-MA potentiated BMA-155Cl-mediated apoptotic cell death. This compound dose-dependently increased the mRNA and protein levels of Beclin-1, NF-κB p65, p53, and Bax, but decreased the expression of IκB and Bcl-2. Pretreatment with BAY 11-7082, a specific inhibitor of NF-κB p65, blocked BMA-155Cl-induced expression of autophagy-and apoptosis-associated proteins. BMA-155Cl administration effectively suppressed the growth of HepG-2 xenografts in vivo, and increased the protein expression levels of LC3B, Beclin-1, NF-κB p65, and Bax in vivo. We conclude that the NF-κB p65 pathway is involved in BMA-155Cl-triggered autophagy, followed by apoptosis in HepG-2 cells in vitro and in vivo. Hence, BMA-155Cl could be a promising pro-apoptotic candidate for developing as a novel anti-cancer drug.
Introduction
Apoptosis and autophagy are two different types of programmed cell death [1] [2] [3] . Apoptosis is regulated by various molecules (such as Bcl-2 family proteins), in particular by antiapoptotic proteins (such as Bcl-2) and pro-apoptotic proteins (such as Bax and BAK). Deficiency in Bax and BAK or reduced expression of Bcl-2 suppresses apoptosis, thereby promoting tumorigenesis [2, 4] . Autophagy is an evolutionarily conserved process in response to nutrient starvation, metabolic stress, intracellular damage, exposure to chemotherapeutic agents, DNA damage, and viral infection; autophagy is important in maintaining the cellular microenvironment [5, 6] . Autophagy is also essential for long-term survival during growth factor withdrawal or cellular stress. This process serves as an adaptive response by providing nutrients and removing damaged macromolecules and organelles. However, autophagic cells coping with excessive stress may commit suicide by undergoing autophagic cell death [4] . Autophagy plays an important role in the regulation of cell survival and cell death, especially in apoptosis-signaling pathways [7] . Considerable cross-talk exists between autophagy and apoptosis. Accumulated evidence suggests that both processes share common components and promote cross-functional mutual regulation via PI3K/AKT signaling, NF-κB sig-
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Bisindolylmaleimide alkaloid BMA-155Cl induces autophagy and apoptosis in human hepatocarcinoma HepG-2 cells through the NF-κB p65 pathway www.chinaphar.com Sun X et al Acta Pharmacologica Sinica naling, and Bcl-2 family members [2, 8] . The cross-talk between apoptosis and autophagy is critical to cell fate but is complicated by the contradictory roles of apoptosis and autophagy under some conditions. Autophagy and apoptosis synergistically affect each other [7] . Hepatocellular carcinoma (HCC) is a common primary tumor [9, 10] . With the development of diagnostic imaging and advanced treatments in recent years, clinicians have adopted radical treatment strategies, such as surgical resection, liver transplantation, and radiofrequency ablation therapy. When used as initial treatments, curative techniques are only applicable to a small number of patients with HCC. Total cure for HCC is difficult to achieve because of high recurrence rates caused by multicentric carcinogenesis and intrahepatic metastasis. Hepatic apoptosis is regulated by autophagic activity. The complex interplay between hepatic autophagy and apoptosis determines the degree of hepatic apoptosis and the progression of liver disease. The autophagic pathway may be a novel therapeutic target for liver disease [7] . Therefore, scholars must screen and develop chemical compounds that can effectively inhibit HCC through the autophagic pathway to benefit public health.
The biological potential of indolo [2,3-a] carbazole derivatives has gained significant interest since the discovery of staurosporine, a glycosidic natural product from Streptomyces staurosporeus, in 1977. In 1986, this compound was found to be a non-specific nanomolar inhibitor of PKC in vitro and was regarded as a new platform for the design of potent, non-toxic, and selective antiproliferative agents [11, 12] . Bisindolylmaleimides, a series of derivative compounds, have received considerable attention in clinical trials, and they exhibit potential as anti-cancer drugs [13] . In the current study, BMA-155 exhibited distinct inhibitory activity in HepG-2 cells in vitro and in vivo. BMA-155 is a new derivative chemically synthesized from indole. Bisindolylmaleimides, such as arcyriarubin A, arcyriaflavin A, and staurosporine, can be dissolved in organic solvents (eg, DMSO) [14] . However, BMA-155 was easily salifiable to form BMA-155Cl, which could be dissolved in PBS; hence, BMA-155 has important potential for clinical applications.
We speculate that BMA-155Cl-induced autophagy and apoptosis exhibit broad spectrum effects. BMA-155Cl induces protective autophagy followed by apoptosis, and this action is associated with the NF-κB p65 signaling pathway in HepG-2 cells in vitro and in vivo.
Materials and methods

Materials
BMA-155 and its hydrochloride, BMA-155Cl, were synthesized by Zhu's group and identified by ESI-MS, 1 H and 13 C NMR data ( Figure 1 ). BMA-155Cl was readily prepared by treating BMA-155 with HCl/ethyl acetate (3 mol/L). The purified BMA-155Cl (over 99% pure) was dissolved in dimethyl sulfoxide (DMSO, AppliChem, Germany) and diluted according to experimental requirements in vitro (the final concentration of DMSO was 4 µL/mL). 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), 3-methyladenine (3-MA, 5 mmol/L), monodansylcadaverine (MDS, 0.05 mmol/L), and 4',6-diamidino-2-phenylindole (DAPI) were purchased from Sigma Co, USA. An Annexin V-FITC Apoptosis Detection Kit was obtained from BD Biosciences, USA. NF-κB p65 and IκB antibodies were purchased from Cell Signaling Technology (CST, USA (USA). LC3B (SC-134226) and Beclin-1 (SC-10086) were obtained from Santa Cruz Biotechnology, Inc, USA. These were all rabbit monoclonal antibodies. A mouse monoclonal anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibody was acquired from Zhongshan Jinqiao Biotechnology (Beijing, China). The NF-κB p65 inhibitor (BAY 11-7082, 10 μmol/L) and lysosomal protease inhibitors (pepstatin A, 10 μg/mL) were purchased from Beyotime (Shanghai, China). All other chemicals used in the experiments were commercial reagent grade products.
Cell culture
Human HCC cell lines (HepG-2, SMMC-7721, and Plc-prf-5) and human normal hepatocyte cell lines (LX-2, HL7702) were purchased from the Shanghai Institute for Biological Sciences (SIBS), Chinese Academy of Sciences and cultured in RPMI-1640 medium (HyClone) containing 10% fetal bovine serum (FBS) supplemented with 100 units/mL penicillin and 100 µg/mL streptomycin at 37 °C in a humidified atmosphere of 5% CO 2 .
MTT assay
The cytotoxicity of BMA-155Cl was evaluated with MTT assays [2] . Cells (HepG-2, SMMC-7721, Plc-prf-5, LX-2, and HL7702) were seeded in 96-well plates (4×10 3 -5×10 3 cells per well) overnight. After 24 h of incubation, cells were treated with or without 3-MA (5 mmol/L per well) 1 h prior to the administration of BMA-155Cl for the indicated time periods. To each well, 12 μL of MTT (5 mg/mL) was added, and then, cells were incubated at 37 °C for 4 h. The medium with MTT was removed, and 150 μL/well DMSO was added to dissolve the formed purple formazan crystals. Cell viability was assessed by recording the absorbance at 570 nm with a microplate reader (Bio-Rad 680). The cell inhibition ratio was cal- 
Observation of morphological changes
Briefly, 5×10 4 cells/well (HepG-2, HL7702, and Plc-prf-5) were seeded in six-well culture plates. HepG-2 cells were incubated with or without 10 μmol/L BMA-155Cl for the indicated time periods (12 and 24 h). HL7702 cells were incubated with 10 and 20 μmol/L BMA-155Cl for 24 h. Plc-prf-5 cells were incubated with 5 and 10 μmol/L BMA-155Cl for 24 h. Cellular morphology was observed with a phase-contrast microscope (Nikon, TI-SR, Japan).
Transmission electron microscopy (TEM)
HepG-2 cells were treated or not treated with 10 μmol/L BMA-155Cl for the specified time periods. The cells were harvested with a cell scraper, centrifuged, fixed with 3% glutaraldehyde for 1 h at room temperature, and centrifuged again. Post-fixation, cells were treated with 0.15 mol/L phosphate buffer containing 3% osmium tetroxide for 1 h, followed by rapid wash in the same buffer. The specimens were dehydrated with alcohol-water solutions of varying concentrations and 100% propylene oxide. The specimens were then embedded with a 1:1 mixture of propylene oxide:araldite (v/v) for 1 h, followed by 1: 3 mixtures overnight at room temperature. Polymerization was induced at 60 °C for 3-4 d after treatment in undiluted resin for 1 h. Sections stained with 1% toluidine blue were placed on copper grids and observed with a transmission electron microscope (JEM-1200EX, Japan) at 60 kV.
Analysis of MDC staining
HepG-2 cells (2×10 4 cells/well) were seeded into 24-well plates with round 12-mm-diameter glass cover slips. After 24 h of incubation, the cells were treated with or without 3-MA (5 mmol/L per well) 1 h prior to administration of BMA-155Cl for 24 h. The cells were incubated in 0.05 mmol/L monodansylcadaverine (MDC) at 37 °C for 1 h. Coverslips containing cells were then mounted on microscope slides using mounting medium (PBS: glycerol=1:1). Changes in fluorescence were observed with confocal microscopy (ZEISS, LSM700, Germany). MDC staining was used to confirm the abundance of autophagic vacuoles in cells. The MDC-positive ratio was calculated by the following formula [15] : MDC-positive ratio (%)=[MDC-positive cell counts/100 cells]×100.
Cells with the same treatment were analyzed by flow cytometry. Cellular fluorescence was determined to estimate MDC intensity, and the results were analyzed with WinMDI 2.9 software.
GFP-LC3 localization observed with confocal microscopy GFP-LC3 U87 cells (2×10 4 cells/well) were seeded into round 12-mm-diameter glass cover slips in 24-well plates. After 24 h of incubation, the cells were treated with or without 3-MA (5 mmol/L/well) 1 h prior to the administration of BMA-155Cl for 24 h. Then, cells were stained with 1 μg/mL DAPI for 10 min at room temperature. After washing three times with PBS-TX, coverslips containing cells were mounted on microscope slides and analyzed by confocal microscopy (ZEISS, LSM700, Germany).
Apoptotic bodies stained with DAPI observed using confocal microscopy HepG-2 cells (2×10 4 cells/well) were seeded into round 12-mm-diameter glass cover slips in 24-well plates. After 24 h of incubation, the cells were treated with or without 3-MA (5 mmol/L per well) 1 h prior to administration of BMA155Cl for 24 h. Cells were stained with 1 μg/mL DAPI for 10 min at room temperature. After washing three times with PBS-TX, coverslips containing cells were mounted on microscope slides and analyzed using confocal microscopy (ZEISS, LSM700, Germany). Cell viability (%)=[1-(DAPI positive cell counts of experimental group/DAPI positive cell counts of control)]×100. To assess autophagy, cells were incubated with 0.05 mmol/L monodansylcadaverine (MDC) at 37 °C for 1 h. According to the manufacturer's instructions, the samples were analyzed by flow cytometry (Becton Dickinson, USA). The apoptotic data were post-processed with WinMDI 2.9 analysis software.
RNA extraction and relative quantification using real-time PCR Total RNA was extracted using an RNAEasy kit according to the manufacturer's instructions (Bioecon Biotec Co Ltd, China). RNA purity was checked by measuring the OD 260/280 of RNA samples (>1.8). cDNA was synthesized through reverse transcription using M-MLV reverse transcriptase and oligo(dT) primer. The gene expression levels of NF-κB p65, p53, Beclin-1, and Bax were detected by real-time PCR. PCR amplification was performed in an eight-tube strip format (Axygen, Union City, CA) in triplicate. Each reaction contained 1×SYBR Green PCR Master mix, 1 μmol/L forward and reverse primers, and 1 μL of template cDNA to obtain a final volume of 20 μL, and PCR was performed using a Mastercycler ep realplex apparatus (Eppendorf, Germany). The following primers were used: primers based on the NF-κB p65 gene (forward: 5′-GAGGACTGCTGCTACGTCAC-3′ and reverse: 5′-ACCAGGTTCAGGTTCAGCTC-3′), Beclin-1 gene (forward: 5′-CCACAGCCCAGGCGAAACCA-3′ and www.chinaphar.com Sun X et al Acta Pharmacologica Sinica reverse: 5′-CCGCCATCAGATGCCTCCC-3′), p53 gene (forward: 5'-TAACAGTTCCTGCATGGGCGGC-3' and reverse: 5′-AGGACAGGCACAAACACGCACC-3′), and the Bax gene (forward: 5′-TCAACTGGGGCCGGGTTGTC-3′ and reverse: 5′-CCTGGTCTTGGATCCAGCC-3′). Evaluation of the GAPDH expression was utilized as a control for RNA amount and was conducted with a primer (forward: 5′-GACGGCCG-CATCTTCTTGT-3′ and reverse: 5′-CACACCGACCTTCAC-CATTTT-3′) [16] [17] [18] . Amplification was performed for 45 cycles of sequential denaturation (95 °C, 2 min); annealing (60 °C, 15 s); and extension (72 °C, 20 s). A Mastercycler ep realplex was used to obtain real-time PCR assay data. Each fluorescent reporter signal was measured against the internal reference dye signal to normalize the non-PCR-related fluorescence fluctuations among the wells. All samples were studied in independent triplicate experiments. All primers were synthesized by Sangon Co, Ltd (Shanghai, China).
Isolation of nuclear and cytosolic fractions and Western blot analysis
Cells were separated into two fractions, nuclear and cytosolic, using a Nuclear and Cytoplasmic Protein Extraction Kit (Beyotime Inst, Haimen, China). The treated cells were washed with ice-cold PBS and suspended in 200 μL of Reagent A containing 1 mmol/L PMSF. The cells were vortexed for 5 s, incubated on ice for 15 min, and 10 μL of Reagent B was added. The above procedure was repeated. The precipitate contained the nuclei separated from the cytosolic extracts by centrifugation (16 000×g, 5 min at 4 °C). The supernatant liquid was the cytosolic fraction. The nuclear pellets were resuspended in nuclear protein reagent for 30 min at 4 °C under agitation. The nuclear proteins remained in the supernatants after centrifugation (16 000×g, 10 min at 4 °C). The cells were lysed with whole-cell extraction buffer [50 mmol/L Tris-HCl, 2% sodium dodecyl sulfate (SDS), 10% glycerol, 100 mmol/L DTT (DL-dithiothreitol)] to obtain whole-cell proteins for western blot analyses. The samples were subjected to 8%-12% SDS-polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes. The membranes were washed with distilled water and blocked with 5% non-fat milk in TBS-T buffer (10 mmol/L Tris-HCl, 150 mmol/L NaCl, and 0.05% [v/v] Tween-20; pH 7.8) for at least 1 h at room temperature. The membranes were incubated in a solution containing monoclonal antibodies specific for NF-κB p65, IκB, LC3B, Beclin-1, p53, p-p53, Bax, Bcl-2, and GAPDH overnight at 4 °C. The membranes were incubated with secondary biotin-conjugated goat anti-mouse IgG or anti-rabbit IgG (diluted 1:1000; Santa Cruz Biotechnology, Inc, USA). Protein expression was quantified by densitometry using Alpha View software [2] .
In vivo xenograft study Balb/c athymic (nu+/nu+) male mice, 5-6 weeks old, were purchased from the Animal Center of China Academy of Medical Sciences (Beijing, China). All animal experiments were performed in accordance with the institutional guidelines of the Animal Care and Use Committee at Shandong University.
Briefly, 2×10 6 HepG-2 cells in 0.1 mL of normal saline (NS) were subcutaneously (sc) injected into the right armpit of one mouse to establish an HCC xenograft model. After 3 weeks, the rapidly proliferating tumor was cut into 1.5-mm-thick pieces and subcutaneously implanted into the right armpit of nude mice with a puncture needle. Tumor sizes were measured with a caliper. When the tumors grew to approximately 100 mm 3 , the tumor-bearing mice were randomly separated into four groups (n=6/group): vehicle (NS), vincristine (0.4 mg/kg), and BMA-155Cl (10 and 20 mg/kg). All drugs and vehicle were intraperitoneally (ip) injected into the mice once every 3 d, for a total of 18 d. The tumor volumes and the body weights of the mice were measured every 3 d. Inhibition of cancer growth was defined as the ratios of the weight and volume of experimental tumors to those of the vehicle control tumors. At the end of the experiments, the mice were euthanized, and tumor tissues were excised. The tissues were homogenized to extract proteins for Western blot analysis and prepare slices for H&E staining and immunohistochemistry (IHC).
IHC and H&E staining IHC and HE staining were performed by Shandong Academy of Medical Sciences. IHC was performed using an SP-9000 Histostain TM -Plus Kit (Beijing Zhongshan Golden Bridge Biotechnology Co, Ltd) according to the manufacturer's instructions. LC3B, Beclin-1, NF-κB p65, and IκB antibodies were diluted at 1:100. HE staining was conducted using a DAB Kit (Beijing Zhongshan Golden Bridge Biotechnology Co, Ltd) according to the manufacturer's instructions. Images were captured with a fluorescence microscope (Nikon, TI-SR, Japan) in brightfield. Staining intensity was scored as 0 (negative), 1 (weak), 2 (medium), or 3 (strong). The extent of staining was scored as 0 (0%), 1 (1%-25%), 2 (26%-50%), 3 (51%-75%), or 4 (76%-100%) according to the percentage of the positively stained area in the entire carcinoma area [19, 20] . The sum of the intensity and extent score was considered the final staining score for NF-κB p65, IκB, LC3B, Beclin-1, Bax, and Bcl-2.
Statistical analysis
All experiments were performed at least three times. Statistical analysis was performed with analysis of variance (ANOVA), followed by Tukey's t-test. P-values <0.05 were considered statistically significant.
Results
Antitumor effect of BMA-155Cl in vitro and in vivo We used an MTT colorimetric assay to determine the cytotoxic effect of BMA-155Cl on human hepatocarcinoma and normal liver cells. Three human hepatocarcinoma cell lines (HepG-2, SMMC-7721, and Plc-prf-5), a human hepatic stellate cell line, LX-2, and a normal HL7702 cell line were treated with BMA155Cl for 24, 48, and 72 h. As shown in Table 1 (Figure 2A ). The anti-tumor effect of BMA-155Cl was further evaluated in vivo in nude mice bearing HepG-2 xenografts. The tumor volumes in the experimental groups grew more slowly than in the vehicle control group ( Figure 2B ). The body weight significantly decreased in the experimental groups, especially in the vincristine-treated group ( Figure 2C ). After treatment with 10 and 20 mg/kg BMA-155Cl, HepG-2 xenografts exhibited a 31.5% and 51.0% reduction in weight, respectively, and a 34.6% and 59.4% reduction in tumor volume, respectively. Vincristine (0.4 mg/kg) exhibited superior inhibitory activity on HepG-2 xenografts (with tumor weight inhibition of 63.6% and tumor volume inhibition of 77.9%) ( Table 2 ). BMA155Cl injection was generally well tolerated by mice with no significant loss of body weight compared with the vincristinetreated group ( Figure 2C ). HE staining showed necrosis of the tumor tissue in the group injected with 20 mg/kg BMA-155Cl, whereas tumors in the vehicle control group displayed abundant blood vessels and vigorous growth ( Figure 2D ).
BMA-155Cl induces autophagy in vitro
Autophagy and apoptosis were observed in BMA-155Cl-treated cells using an inverted optical microscope ( Figure 3A) .
Vacuoles induced by BMA-155Cl formed as early as 6 h posttreatment. The number and size of the vacuoles increased progressively with prolonged treatment. After 12 h of incubation with 10 µmol/LBMA-155Cl, the cells exhibited cytoplasmic vacuolization (indicated by blank arrow, as shown in Figure  3A ; 12 h). By contrast, prolonged BMA-155Cl treatment up to 24 h resulted in apoptosis, which was characterized by nuclear condensation and segregation (indicated by white arrow, as shown in Figure 3A ; 24 h), without increasing the number of autophagic vacuoles.
The ultrastructural details in BMA-155Cl-treated cells were further examined by TEM. Treatment with BMA-155Cl resulted in the appearance of numerous vacuoles in HepG-2 cells in contrast to control cells ( Figure 3B) . At 15 h, we clearly observed double membrane-bound vacuoles containing organelles and cellular fragments, indicating that they were autolysosomes [2] . Extending the treatment with BMA-155Cl to 24 h resulted in apoptotic cell death, characterized by nuclear condensation and segregation (indicated by white arrow, as shown in Figure 3B ; 24 h) in contrast to autophagic cells.
In addition, using flow cytometry, we confirmed that BMA155Cl induced autophagy. As shown in Figure 3C and 3D, BMA-155Cl increased the number of autolysosomes stained with MDC in a dose-and time-dependent manner in HepG-2 cells. The level of autophagy was highest at 10 µmol/L and 15 h, indicating that 10 µmol/L BMA-155Cl induced the most 
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Established tumors were treated with BMA-155Cl by injection intraperitoneally. Body weight and tumor volume were examined before and after drug administration. Tumor weight was measured after mice were sacrificed. Tumor weight inhibition (%)=(1-tumor weight of experimental group/ tumor weight of vehicle group)×100%; Tumor volume inhibition (%)=( To confirm the broad spectrum effect of BMA-155Cl on autophagy induction, we also observed HL7702, Plc-prf-5 and GFP-LC3 U87 cells after treatment with BMA-155Cl for 24 h. BMA-155Cl induced autophagy in HL7702 and Plcprf-5 cells ( Figure 3E ) and the recruitment of GFP-LC3 during autophagosome formation ( Figure 5H ).
BMA-155Cl induces apoptosis in HepG-2 cells in vitro
Flow cytometry analysis showed that treatment with 5, 10, and 20 µmol/L BMA-155Cl for 24 h increased the number of apoptotic cells by 24.81%, 37.35%, and 50.72%, respectively ( Figure  4A ). BMA-155Cl time-dependently induced apoptosis in HepG-2 cells. After treatment with BMA-155Cl for 12, 24, and 48 h, the apoptotic ratios were 28.09%, 34.04%, and 48.60%, respectively ( Figure 4B ). (Figures 5B and C) . In addition, MDC staining showed that 3-MA suppressed the formation of autophagosomes at the early stages of autophagy to exert an autophagy-inhibiting effect ( Figure 5D ). The MDC-positive ratio decreased from 58.76% (group treated with 10 µmol/L BMA-155Cl alone) to 33.58% (group treated with 10 µmol/L BMA-155Cl in the presence of 5 mmol/L 3-MA) ( Figure 5F ). We used DAPI staining to observe the formation of BMA-155Cl-induced apoptotic bodies. BMA-155Cl dose-dependently induced apoptosis We set LR+UR as apoptosis rate). To further analyze the mechanism of BMA-155Cl-induced autophagy followed by apoptosis in HepG-2 cells, we evaluated the effect of BMA-155Cl on the mRNA levels of NF-κB, Beclin-1, p53, and Bax through real-time quantitative RT-PCR analysis. The results showed that BMA-155Cl increased NF-κB, Beclin-1, p53, and Bax gene expression in a timedependent manner ( Figure 6A ). Beclin-1 was activated prior to Bax, and the activation of NF-κB mRNA peaked as early as approximately 4 h. Hence, the NF-κB signaling pathway is involved in autophagic apoptosis in BMA-155Cl-treated HepG-2 cells. We predict that autophagy occurred prior to apoptosis.
BMA-155Cl modulates the expression of Beclin-1, LC3B, p53, p-p53, Bax, and Bcl-2 in vitro We also tested the expression of Beclin-1, LC3B, p53, p-p53, Bax and Bcl-2 using a Western blot analysis ( Figure 6B and C). Treatment with BMA-155Cl increased the protein expression of Beclin-1, LC3B, p53, p-p53, and Bax in HepG-2 cells but decreased the expression of Bcl-2, an important anti-apoptosis protein. Interestingly, treatment with 10 µmol/L BMA-155Cl for 24 h slightly decreased the LC3B expression and steadily increased the Bax expression compared with treatment for 12 h. Hence, BMA-155Cl induced protective autophagy followed by apoptosis ( Figure 6C ). Interpretation of the results of LC3 immunoblotting is problematic because LC3B itself is degraded by autophagy. To determine whether BMA-155Cl induced the formation of autophagy or suppressed the degradation of autophagy, we tested the expression of LC3B in samples in the presence and absence of pepstatin A (a lysosomal protease inhibitor, 10 μg/mL). Pretreatment with pepstatin A for 1 h enhanced the LC3B level compared with treatment with 10 µmol/L BMA-155Cl alone for 24 h ( Figure 6D ). Hence, BMA-155Cl induced the occurrence of autophagy.
BMA-155Cl modulates the expression of NF-κB p65 and IκB NF-κB is an important transcription factor that regulates the synthesis and secretion of various cytokines and chemokines in response to immunological stimuli; as such, we examined the role of NF-κB in BMA-155Cl-induced autophagy and apoptosis in HepG-2 cells using a Western blot [21] . NF-κB p65 activation and deactivation are mediated by phosphorylation and degradation of IκB protein. The nuclear translocation of NF-κB p65 is an important characteristic of autophagy [22] . Our results showed that BMA-155Cl treatment dose-dependently enhanced NF-κB p65 expression but decreased IκB expression in the total protein extracts ( Figure 6B ). We also determined NF-κB p65 protein levels in different cellular fractions (ie, the nucleus and cytoplasm) with a Western blot analysis. Compared with the control, BMA-155Cl-induced HepG-2 cells exhibited considerably increased expression of NF-κB p65 in the nucleus but decreased expression in the cytoplasm ( Figure  6F ).
Inhibition of NF-κB suppresses the activation of p53, p-p53, LC3B, and Bax in BMA-155Cl-induced apoptotic cell death To understand the mechanism of NF-κB p65 in BMA-155Cl-induced autophagy and apoptosis, we examined the expression levels of p53, p-p53, LC3B, Bax, and Bcl-2 in the absence or presence of 10 μmol/L BAY 11-7082 (a specific inhibitor of NF-κB p65). Treatment with 10 μmol/L BAY 11-7082 alone showed minimal cytotoxicity to HepG-2 cells, with cell viability of approximately 93.27%±2.2%. A decreased level of p53, p-p53, LC3B, and Bax and an increased level of Bcl-2 in the presence of 10 μmol/L BAY 11-7082 compared with BMA-155Cl treatment alone confirmed the involvement of NF-κB p65 in BMA-155Cl-induced autophagy and apoptosis in HepG-2 cells ( Figure 6E ).
BMA-155Cl regulates autophagy and apoptosis through the NF-κB p65 pathway in vivo Finally, we tested the expression of Beclin-1, LC3B, NF-κB, IκB, Bax, and Bcl-2 after treatment with BMA-155Cl in HepG-2 xenografts using a Western blot ( Figure 7A and 7B) . BMA155Cl increased the protein expression of Beclin-1, LC3B, NF-κB p65, and Bax and decreased the protein expression of Bcl-2 and IκB. IHC results also demonstrated similar expression levels of Beclin-1, LC3B, Bax, Bcl-2, NF-κB p65, and IκB in BMA-155Cl-treated HepG-2 xenografts; this finding significantly differed from that of the control ( Figure 7C ).
Discussion
Various bisindolylmaleimide derivatives have been synthesized to reduce the cytotoxicity and improve the anti-tumor activity of drugs for clinical applications [13, 23] . Despite the potent activity, most compounds have limited water solubility because of their hydrophobic nature, thereby restricting in vivo studies. Alkylation of the side chains of the indole nitrogen plays an important role in the anti-tumor activity of these compounds. In a preliminary screening, we found that treatments with BMA-155Cl for 24 h induced autophagy and the recruitment of GFP-LC3 in HL7702, Plc-prf-5, and GFP-LC3 U87 cells during autophagosome formation; this finding confirms the broad spectrum effect of BMA-155Cl on autophagy induction. This phenomenon was clearly observed in HepG-2 cells. Notably, BMA-155 is a new and easily salifiable bisindolylmaleimide compound with potential as a therapeutic drug in vivo. Thus, we chose HepG-2 cells for the experiments using BMA-155 salts (specifically, BMA-155Cl) in vitro and in vivo.
Apoptosis and autophagy are two different processes of programmed cell death (PCD). Apoptosis controls the intercellular steady state and the development of individual organisms [24] . The induction of autophagy, which is known to maintain cell survival under conditions of cellular stress, such as a shortage of nutrients, metabolic stress, and intracellular damage, is a common survival mechanism in eukaryotic cells [4] . Many reports have demonstrated that apoptosis and autophagy exhibit complex relationships, and many gene-and protein-controlled apoptosis pathways regulate autophagy.
In this study, autophagosomes markedly accumulated at the early stages of autophagy (at approximately 6 h) in BMA155Cl-treated cells and peaked at approximately 15 h, as observed through TEM analysis. With MDC staining and observation using fluorescence microscopy and flow cytometry (FCM), we confirmed the autophagy activity, consis- Figure 7 . BMA-155Cl regulates autopahgy and apoptosis through NF-κB p65 pathway in vivo. Western blot and its quantification results indicated that BMA-155Cl enhanced levels of LC3B, Beclin-1, NF-κB, and Bax, whereas decreased the levels of IκB and Bcl-2 (A, B). The corresponding histograms quantified through densitometry were presented as C and D. The data were expressed as the mean±SD of triplicate independent experiments. (E) The expressions of NF-κB p65, IκB, Beclin-1, LC3B, Bax, and Bcl-2 in the tumor tissues were determined by immunohistochemical analysis. Magnification ×200. NF-κB, a ubiquitous transcription factor, has been implicated in the control of apoptosis and autophagy [25, 26] . NF-κB, along with many of its downstream target genes, such as the Bcl-2 family and p53, plays important roles in mediating apoptosis in response to many stimulations, including cancer therapeutic agents [24, 27, 28] . Accumulated evidence shows that the activation of NF-κB is primarily modulated by a complex formed by NF-κB and IκB in the cytoplasm of non-stimulated cells. Extracellular stimuli cause rapid phosphorylation of IκB (inhibitor of NF-κB), which is subsequently subjected to ubiquitination and proteasome degradation [29] . The complete degradation of IκB leads to rapid and transient activation of NF-κB and subsequent nuclear translocation [30] . The p53 transcription factor responds to several stimuli, such as DNA damage, hypoxia, and even oncogene activation. Activation of the p53 transcription factor can lead to the translation of various genes, which regulate cell fate by initiating cell cycle arrest, apoptosis, senescence, and even autophagy [31, 32] . The p53 protein can be modified by acetylation, phosphorylation, methylation, ubiquitination, sumoylation, neddylation, and glycosylation and is mainly degraded in the cytosol [32] . p53 can also enhance the transcription of the pro-apoptotic BH3-only proteins, Noxa and Puma, which indirectly promote Bax activation by inhibiting the function of the anti-apoptotic proteins, Bcl-2 or Bcl-xL, leading to apoptosis [30] . Emerging evidence has revealed that p53 and NF-κB signaling are linked to each other via metabolic regulation and regulation of cellular senescence and aging. WIP1 and MIF are important proteins that link p53 and NF-κB signaling cascades to each other [32] . In addition, inhibition of NF-κB abrogated p53-induced apoptosis in a p53-inducible Saos-2 cell line; the loss of p65 (a subunit of NF-κB) can also cause resistance to different agents that induce apoptosis through p53 [25, 33, 34] . In this study, RT-PCR and Western blot analyses showed that BMA-155Cl increased the expression of NF-κB p65, p53, and p-p53 but decreased the expression of IκB. This finding indicates that functional NF-κB p65 and p53 are required for BMA-155Cl-mediated inhibition of the growth of HepG-2 cells. Moreover, BMA-155Cl increased NF-κB p65 levels in the nucleus but not in the cytoplasm, indicating that BMA-155Cl activated NF-κB p65, which transferred to the nucleus and positively regulated apoptosis.
To investigate the role of NF-κB p65 in BMA-155Cl-induced apoptosis and autophagy, we pretreated HepG-2 cells with BAY 11-7082. In vitro studies showed that the inhibition of NF-κB p65 by BAY 11-7082 decreased the expression of p53, p-p53, and the pro-apoptosis protein Bax but increased the expression of the anti-apoptosis protein Bcl-2. Our results revealed that NF-κB p65 indirectly regulated BMA-155Cl-induced apoptosis through p53 in HepG-2 cells.
Microtubule-associated protein light chain 3 (LC3), a human homolog of yeast Atg8, plays an essential role in autophagy. LC3 is cleaved to produce a cytosolic 18-kDa protein called LC3-I, which is further converted to LC3-II, a 16-kDa protein that can conjugate phosphatidylethanolamine to localize in autophagosomal membranes and is an autophagy marker [35, 36] . Enhancement of autophagy can result in the accumulation of LC3 puncta. Another important factor for autophagosome formation is Beclin-1, a 60-kDa protein encoded by the Beclin-1 gene. This protein regulates autophagosome formation through binding to class III PI3K [7] . In this study, RT-PCR and Western blot results showed that BMA-155Cl increased the expression of Beclin-1 and LC3B and the amount of LC3B that accumulated in the presence of pepstatin A, indicating the occurrence of autophagy induced by BMA-155Cl in HepG-2 cells. Moreover, inhibition of NF-κB p65 by BAY 11-7082 decreased the expression of LC3B, revealing that NF-κB p65 directly regulated BMA-155Cl-induced autophagy in HepG-2 cells.
An in vivo assay showed that BMA-155Cl inhibited the growth of HepG-2 tumors in mice. HE staining also verified the effective cytotoxicity of BMA-155Cl in vivo. Moreover, IHC results indicated increased expression of NF-κB p65, Beclin-1, LC3B, and Bax in BMA-155Cl-treated HepG-2 xenografts and decreased expression levels of Bcl-2 and IκB. This finding further confirms that BMA-155Cl can induce autophagy and apoptosis in vivo.
Autophagy plays an important role in protection against infections, cancers, neurodegeneration, aging, and heart diseases [7, 37, 38] . However, other studies have revealed that inhibition of autophagy is enhanced in colon cancer cells, such as human osteosarcoma U2OS cells and HeLa cells [2, 39, 40] . Thus, the role of autophagy remains controversial. The results of our study showed that inhibition of autophagy with 3-MA enhanced BMA-155Cl-induced apoptosis in HepG-2 cells, thereby suggesting that BMA-155Cl induced a temporary protective autophagy followed by apoptosis. The experimental conditions in this study were strictly controlled to minimize the influence of the environment or external stimuli on cell autophagy [41] .
In conclusion, this study is the first to report that BMA155Cl produced growth inhibition in several types of cancer cells and induced a temporary protective autophagy, followed by apoptosis associated with the NF-κB p65 signaling pathway, in HepG-2 cells both in vitro and in vivo. We speculate that NF-κB p65 regulated the expression of the autophagyassociated protein LC3B and controlled the expression of p53 to control the expression of Bcl-2 family proteins in BMA155Cl-induced HepG-2 cells. Considering the complexity of intracellular signal transduction, other signaling proteins, such as p38 and AKT, may also play important roles in BMA155Cl-induced autophagy and apoptosis in HepG-2 cells [42] . Our results suggest that the BMA-155Cl-induced inhibition of HepG-2 cell growth via autophagy and apoptosis might be a promising anti-tumor candidate. Hence, BMA-155Cl could be a promising pro-apoptotic compound for developing novel anticancer drugs.
